PPAR𝛾 gene and atherosclerosis: Genetic polymorphisms, epigenetics and therapeutic implications

1 Cai J-M, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid ath-erosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation. 2002; 106(11): 1368-1373.CaiJ-MHatsukamiTSFergusonMSSmallRPolissarNLYuanCClassification of human carotid ath-erosclerotic lesions with in vivo multicontrast magnetic resonance imagingCirculation2002106111368–137310.1161/01.CIR.0000028591.44554.F912221054Search in Google Scholar

2 Atherosclerosis. National Heart, Lung, and Blood Institute (NHLBI). Department of Health and Human Services, Bethseda, MD, USA, 2018 (https://www.nhlbi.nih.gov/health-topics/atherosclrerosis).AtherosclerosisNational Heart, Lung, and Blood Institute (NHLBI). Department of Health and Human Services, Bethseda, MD, USA2018(https://www.nhlbi.nih.gov/health-topics/atherosclrerosis)Search in Google Scholar

3 Roy S. Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol. N Am J Med Sci. 2014; 6(5): 191-198.RoySAtherosclerotic cardiovascular disease risk and evidence-based management of cholesterolN Am J Med Sci201465191–19810.4103/1947-2714.132916404905124926443Search in Google Scholar

4 Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J. 2010; 40(1): 1-9.HongYMAtherosclerotic cardiovascular disease beginning in childhoodKorean Circ J20104011–910.4070/kcj.2010.40.1.1281279120111646Search in Google Scholar

5 Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. Mediators Inflamm. 2015; 2015: 18329.AmmiratiEMoroniFNorataGDMagnoniMCamiciPGMarkers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosisMediators Inflamm201520151832910.1155/2015/718329441546925960621Search in Google Scholar

6 Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473(7347): 317-325LibbyPRidkerPMHanssonGKProgress and challenges in translating the biology of atherosclerosisNature20114737347317–32510.1038/nature1014621593864Search in Google Scholar

7 Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.RossRAtherosclerosis – An inflammatory diseaseN Engl J Med19993402115–12610.1056/NEJM1999011434002079887164Search in Google Scholar

8 Kruszynska YT, Mukherjee R, Jow L, Dana S, Paterniti JR, Olefsky JM. Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitus. J Clin Invest. 1998; 101(3): 543-548.KruszynskaYTMukherjeeRJowLDanaSPaternitiJROlefskyJMSkeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non-insulin-dependent diabetes mellitusJ Clin Invest19981013543–54810.1172/JCI10765085969449686Search in Google Scholar

9 Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev. 1999; 20(5): 649-688.DesvergneBWahliWPeroxisome proliferator-activated receptors: Nuclear control of metabolismEndocr Rev1999205649–68810.1210/edrv.20.5.038010529898Search in Google Scholar

10 Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev. 2008; 18(5): 461-467.HongCTontonozPCoordination of inflammation and metabolism by PPAR and LXR nuclear receptorsCurr Opin Genet Dev2008185461–46710.1016/j.gde.2008.07.016264101418782619Search in Google Scholar

11 Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res. 2004; 45(12): 2161-2173.LiACGlassCKPPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosisJ Lipid Res200445122161–217310.1194/jlr.R400010-JLR20015489539Search in Google Scholar

12 Yongsakulchai P, Settasatian C, Settasatian N, Komanasin N, Kukongwiriyapan U, Cote ML, et al. Association of combined genetic variations in PPARγ, PGC-1α, and LXRα with coronary artery disease and severity in Thai population. Atherosclerosis. 2016; 248: 140-148.YongsakulchaiPSettasatianCSettasatianNKomanasinNKukongwiriyapanUCoteMLAssociation of combined genetic variations in PPARγ, PGC-1α, and LXRα with coronary artery disease and severity in Thai populationAtherosclerosis2016248140–14810.1016/j.atherosclerosis.2016.03.00527016616Search in Google Scholar

13 Al-Shali KZ, House AA, Hanley AJGG, Khan HMRR, Harris SB, Zinman B, et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke. 2004; 35(9): 2036-2040.Al-ShaliKZHouseAAHanleyAJGGKhanHMRRHarrisSBZinmanBGenetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosisStroke20043592036–204010.1161/01.STR.0000138784.68159.a515284449Search in Google Scholar

14 Wang L, Zhao L, Cui H, Yan M, Yang L, Su X. Association between PPARγ2 Pro 12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China. Genet Mol Res Mol Res. 2012; 11(113): 2929-2938.WangLZhaoLCuiHYanMYangLSuXAssociation between PPARγ2 Pro 12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, ChinaGenet Mol Res Mol Res2012111132929–293810.4238/2012.May.18.1322653647Search in Google Scholar

15 Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen M-R, Frick MH, et al. Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002; 105(12): 1440-1445.FlavellDMJamshidiYHaweEPinedaTorra ITaskinenM-RFrickMHPeroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery diseaseCirculation2002105121440–144510.1161/01.CIR.0000012145.80593.25Search in Google Scholar

16 Li Y, Zhu J, Ding J. Association of the PPARγ2 Pro12Ala polymorphism with increased risk of cardiovascular diseases. Genet Mol Res. 2015; 14(144): 18662-18674.LiYZhuJDingJAssociation of the PPARγ2 Pro12Ala polymorphism with increased risk of cardiovascular diseasesGenet Mol Res20151414418662–1867410.4238/2015.December.28.1526782516Search in Google Scholar

17 Yan ZC, Zhu ZM, Shen CY, Zhao ZG, Ni YX, Zhong J, et al. Peroxisome proliferator-activated receptor γ C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome. Zhonghua Yi Xue Za Zhi. 2004; 84(7): 543-547.YanZCZhuZMShenCYZhaoZGNiYXZhongJPeroxisome proliferator-activated receptor γ C-161T polymorphism and carotid artery atherosclerosis in metabolic syndromeZhonghua Yi Xue Za Zhi2004847543–547Search in Google Scholar

18 Wang P, Wang Q, Yin Y, Yang Z, Li W, Liang D, et al. Association between peroxisome proliferator-activated receptor γ gene polymorphisms and atherosclerotic diseases: A meta-analysis of case-control studies. J Atheroscler Thromb. 2015; 22(9): 912-925.WangPWangQYinYYangZLiWLiangDAssociation between peroxisome proliferator-activated receptor γ gene polymorphisms and atherosclerotic diseases: A meta-analysis of case-control studiesJ Atheroscler Thromb2015229912–92510.5551/jat.2613825832497Search in Google Scholar

19 Rhee EJ, Kwon CH, Lee WY, Kim SY, Jung CH, Kim BJ, et al. No Association of Pro12Ala polymorphism of PPAR-γ gene with coronary artery disease in Korean subjects. Circ J. 2007; 71(3): 338-342.RheeEJKwonCHLeeWYKimSYJungCHKimBJNo Association of Pro12Ala polymorphism of PPAR-γ gene with coronary artery disease in Korean subjectsCirc J2007713338–34210.1253/circj.71.33817322631Search in Google Scholar

20 Wan J, Xiong S, Chao S, Xiao J, Ma Y, Wang J, et al. PPARγ gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus. Cardiovasc Diabetol. 2010; 9(1): 13.WanJXiongSChaoSXiaoJMaYWangJPPARγ gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitusCardiovasc Diabetol2010911310.1186/1475-2840-9-13285985020334678Search in Google Scholar

21 Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008; 102(8): 873-887.MatoukCCMarsdenPAEpigenetic regulation of vascular endothelial gene expressionCirc Res20081028873–88710.1161/CIRCRESAHA.107.17102518436802Search in Google Scholar

22 Yu J, Qiu Y, Yang J, Bian S, Chen G, Deng M, et al. DNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. Sci Rep. 2016; 6(1): 30053.YuJQiuYYangJBianSChenGDengMDNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in miceSci Rep2016613005310.1038/srep30053498764327530451Search in Google Scholar

23 Miranda TB, Jones PA. DNA methylation: The nuts and bolts of repression. J Cell Physiol. 2007; 213(2): 384-390.MirandaTBJonesPADNA methylation: The nuts and bolts of repressionJ Cell Physiol20072132384–39010.1002/jcp.21224Search in Google Scholar

24 Hiltunen MO, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, Mäkinen K, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002; 7(1): 5-11.HiltunenMOTurunenMPHäkkinenTPRutanenJHedmanMMäkinenKDNA hypomethylation and methyltransferase expression in atherosclerotic lesionsVasc Med2002715–1110.1191/1358863x02vm418oaSearch in Google Scholar

25 Reddy MA, Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res. 2011; 90(3): 421-429.ReddyMANatarajanREpigenetic mechanisms in diabetic vascular complicationsCardiovasc Res2011903421–42910.1093/cvr/cvr024Search in Google Scholar

26 Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomäki, Jänne J, Ylä-Herttuala S, et al. Gene ec-sod local hypomethylation in atherosclerosis found in rabbit. Arter Thromb Vasc Biol. 1999; 19(9): 2171-2178.LaukkanenMOMannermaaSHiltunenMOAittomäkiJänne JYlä-HerttualaSGene ec-sod local hypomethylation in atherosclerosis found in rabbitArter Thromb Vasc Biol19991992171–217810.1161/01.ATV.19.9.2171Search in Google Scholar

27 Lund G, Andersson L, Lauria M, Lindholm M, Fraga FM, Villar-Garea A, et al. DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem. 2004; 279(28): 29147-29154.LundGAnderssonLLauriaMLindholmMFragaFMVillar-GareaADNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein EJ Biol Chem20042792829147–2915410.1074/jbc.M403618200Search in Google Scholar

28 Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128(4): 693-705.KouzaridesTChromatin modifications and their functionCell20071284693–70510.1016/j.cell.2007.02.005Search in Google Scholar

29 Clayton AL, Hazzalin CA, Mahadevan LC. Review enhanced histone acetylation and transcription: A dynamic perspective. Mol Cell. 2006; 23(4): 289-296.ClaytonALHazzalinCAMahadevanLCReview enhanced histone acetylation and transcription: A dynamic perspectiveMol Cell2006234289–29610.1016/j.molcel.2006.06.017Search in Google Scholar

30 Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008; 28(5): 812-819.DoranACMellerNMcNamaraCARole of smooth muscle cells in the initiation and early progression of atherosclerosisArterioscler Thromb Vasc Biol2008285812–81910.1161/ATVBAHA.107.159327Search in Google Scholar

31 Chawla A, Boisvert WA, Lee C-H, Laffitte BA, Barak Y, Joseph SB, et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001; 7(1): 161-171.ChawlaABoisvertWALeeC-HLaffitteBABarakYJosephSBA PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesisMol Cell200171161–17110.1016/S1097-2765(01)00164-2Search in Google Scholar

32 Cao Q, Rong S, Repa JJ, St. Clair R, Parks JS, Mishra N. Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development. Arterioscler Thromb Vasc Biol. 2014; 34(9): 1871-1879.CaoQRongSRepaJJSt ClairRParksJSMishraNHistone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development. Arterioscler Thromb Vasc Biol20143491871–187910.1161/ATVBAHA.114.303393421708625035344Search in Google Scholar

33 Cao Y, Lu L, Liu M, Li X-C, Sun R-R, Zheng Y, et al. Impact of epigenetics in the management of cardiovascular disease: A review. Eur Rev Med Pharmacol Sci. 2014; 18(20): 3097-3104.CaoYLuLLiuMLiX-CSunR-RZhengYImpact of epigenetics in the management of cardiovascular disease: A reviewEur Rev Med Pharmacol Sci201418203097–3104Search in Google Scholar

34Peschansky VJ, Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics. 2014; 9(1): 3-12.PeschanskyVJWahlestedtC.Non-coding RNAs as direct and indirect modulators of epigenetic regulationEpigenetics20149131210.4161/epi.27473392818324739571Search in Google Scholar

35 Toba H, Cortez D, Lindsey ML, Chilton RJ. Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep. 2014; 16(2): 386.TobaHCortezDLindseyMLChiltonRJApplications of miRNA technology for atherosclerosisCurr Atheroscler Rep201416238610.1007/s11883-013-0386-9436266424395388Search in Google Scholar

36 Zhao R, Feng J, He G. miR-613 Regulates cholesterol efflux by targeting LXRα and ABCA1 in PPARγ activated THP-1 macrophages. Biochem Biophys Res Commun. 2014; 448(3): 329-334.ZhaoRFengJHeGmiR-613 Regulates cholesterol efflux by targeting LXRα and ABCA1 in PPARγ activated THP-1 macrophagesBiochem Biophys Res Commun20144483329–33410.1016/j.bbrc.2014.04.05224751522Search in Google Scholar

37 Raitoharju E, Lyytikäinen L-P, Levula M, Oksala N, Mennander A, Tarkka M, et al. miR-21, miR-210, miR-34a, And miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011; 219(1): 211-217.RaitoharjuELyytikäinenL-PLevulaMOksalaNMennanderATarkkaMmiR-21, miR-210, miR-34a, And miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular StudyAtherosclerosis20112191211–21710.1016/j.atherosclerosis.2011.07.02021820659Search in Google Scholar

38 Ma L, Yang J, Runesha HB, Tanaka T, Ferrucci L, Bandinelli S, et al. Genome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the Framingham heart study data. BMC Med Genet. 2010; 11(1): 55.MaLYangJRuneshaHBTanakaTFerrucciLBandinelliSGenome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the Framingham heart study dataBMC Med Genet20101115510.1186/1471-2350-11-55286778620370913Search in Google Scholar

39 Caolo V, Schulten HM, Zhuang ZW, Murakami M, Wagenaar A, Verbruggen S, et al. Soluble jagged-1 inhibits neointima formation by attenuating notchherp2 signaling. Arterioscler Thromb Vasc Biol. 2011; 31(5): 1059-1065.CaoloVSchultenHMZhuangZWMurakamiMWagenaarAVerbruggenSSoluble jagged-1 inhibits neointima formation by attenuating notchherp2 signalingArterioscler Thromb Vasc Biol20113151059–106510.1161/ATVBAHA.110.21793521330605Search in Google Scholar

40 Cipollone F, Felicioni L, Sarzani R, Ucchino S, Spigonardo F, Mandolini C, et al. A unique microRNA signature associated with plaque instability in humans. Stroke. 2011; 42(9): 2556-2563.CipolloneFFelicioniLSarzaniRUcchinoSSpigonardoFMandoliniCA unique microRNA signature associated with plaque instability in humansStroke20114292556–256310.1161/STROKEAHA.110.59757521817153Search in Google Scholar

41 Gupta D, Jetton TL, Mortensen RM, Duan SZ, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor γ response element in the mouse pdx-1 promoter. J Biol Chem. 2008; 283(47): 32462-32470.GuptaDJettonTLMortensenRMDuanSZPeshavariaMLeahyJLIn vivo and in vitro studies of a functional peroxisome proliferator-activated receptor γ response element in the mouse pdx-1 promoterJ Biol Chem20082834732462–3247010.1074/jbc.M801813200258332118718916Search in Google Scholar

42 Blaschke F, Caglayan E. Peroxisome proliferator-activated receptor γ agonists: Their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am. 2006; 35(3): 561-574.BlaschkeFCaglayanEPeroxisome proliferator-activated receptor γ agonists: Their role as vasoprotective agents in diabetesEndocrinol Metab Clin North Am2006353561–57410.1016/j.ecl.2006.06.00116959586Search in Google Scholar

43 Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998; 83(5): 1818-1820.MinamikawaJTanakaSYamauchiMInoueDKoshiyamaHPotent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetesJ Clin Endocrinol Metab19988351818–182010.1210/jcem.83.5.49329589700Search in Google Scholar

44 Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intra-vascular ultrasound scanning study. Am Heart J. 2003; 146(2): 366.TakagiTYamamuroATamitaKYamabeKKatayamaMMizoguchiSPioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: An intra-vascular ultrasound scanning studyAm Heart J2003146236610.1016/S0002-8703(03)00146-7Search in Google Scholar

45 Ruiz-Narváez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-γ gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction. Am J Clin Nutr. 2007; (86): 1238-1242.Ruiz-NarváezEAKraftPCamposHAla12 variant of the peroxisome proliferator-activated receptor-γ gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarctionAm J Clin Nutr2007861238–124210.1093/ajcn/86.4.123817921408Search in Google Scholar

46 Li J, Zhang S. microRNA-150 inhibits the formation of macrophage foam cells through targeting adiponectin receptor 2. Biochem Biophys Res Commun. 2016; 476(4): 218-224.LiJZhangSmicroRNA-150 inhibits the formation of macrophage foam cells through targeting adiponectin receptor 2Biochem Biophys Res Commun20164764218–22410.1016/j.bbrc.2016.05.09627216461Search in Google Scholar

47 Chinetti G, Zawadski C, Fruchart J, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem Biophys Res Commun. 2004; 314(1): 151-158.ChinettiGZawadskiCFruchartJStaelsBExpression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXRBiochem Biophys Res Commun20043141151–15810.1016/j.bbrc.2003.12.05814715259Search in Google Scholar